The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new ...
Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the ...
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of ...
Just a few days after Astellas Pharma formally unveiled its new five-year corporate strategic plan in Tokyo in late May, Naoki Okamura, the global drugmaker’s representative dir ...
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy. Roche has added a twelfth US indication to Tecentriq (atezolizumab). The ...
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results